Prediction and impact of attacks of Raynaud'S phenomenon, as judged by patient perception

Rheumatology (United Kingdom)

Volumn 54, Issue 8, 2015, Pages 1443-1447

  Hughes, Michael ^a   Snapir, Amir ^b   Wilkinson, Jack ^c   Snapir, Daniel ^b   Wigley, Fredrick M ^d   Herrick, Ariane L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ORION CORPORATION   (Finland)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Impact; Predict; Quality of life; Raynaud's phenomenon; Severity; Systemic sclerosis

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONLINE SYSTEM; PATIENT DECISION MAKING; PERCEPTION; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RAYNAUD PHENOMENON; SELF REPORT; VERY ELDERLY;

EID: 84939487359     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev002     Document Type: Article

References (11)

1. Wigley FM. Clinical practice. Raynaud's phenomenon. N Engl J Med 2002;347:1001-8.
2. Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 2012;8: 469-79.
3. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013;65:1953-62.
4. Stewart M, Morling JR. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2012;11;7:CD006687.
5. Ennis H, Anderson ME, Wilkinson J, Herrick AL. Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2014;1:CD002069.
6. Merkel PA, Herlyn K, Martin RW et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46: 2410-20.
7. De Angelis R, SalaffiF, Grassi W. Health-related quality of life in primary Raynaud phenomenon. J Clin Rheumatol 2008;14:206-10.
8. Chung L, Shapiro L, Fiorentino D et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum 2009;60:870-7.
9. Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000;160:1101-8.
10. Milio G, Corrado E, Genova C et al. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology 2006;45: 999-1004.
11. Shenoy PD, Kumar S, Jha LK et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology 2010;49:2420-8.